Home Blog Page 2089

China’s Sichuan Extends Cultural Tourism Invitations at Global Landmarks

CHENGDU, China, Oct. 18, 2025 /PRNewswire/ — According to Sichuan International Communication Center, on October 17 (Beijing time), the “Sichuan Ease” cultural tourism logo made its global debut simultaneously across five landmark locations worldwide, including Times Square in New York, Westfield Shopping Centre in London, Cross Shinjuku Vision in Tokyo, Wilkie Edge in central Singapore, and MBK Center in Bangkok. The eye-catching visual display aimed to introduce Sichuan’s rich cultural heritage and stunning natural landscapes to a wider international audience.

China’s Sichuan Extends Cultural Tourism Invitations at Global Landmarks
China’s Sichuan Extends Cultural Tourism Invitations at Global Landmarks

The newly unveiled logo design draws inspiration from classical Chinese cloud patterns and the character “Shu” from oracle bone script. Additionally, the logo seamlessly integrates the form of the giant panda with the structure of the Tai Chi diagram, embodying Sichuan’s philosophy of life—a harmonious blend of “leisurely ease” and “openness”.

Inspired by Shu brocade and embroidery, and Zigong lantern art, the logo features rich color combinations. It not only reflects Sichuan’s diverse landscapes—from majestic Danxia landforms to the tranquil bamboo sea—but also conveys a message of cultural vitality and inclusivity.

The simultaneously released promotional video features globally renowned attractions such as Jiuzhaigou Valley, Huanglong Scenic and Historic Interest Area, Daocheng Yading, and Southern Sichuan Bamboo Sea, while showcasing symbols of the ancient Shu civilization like the Sun and Immortal Birds Gold Ornament and the Bronze Head Portrait with Gold Mask, in order to pay tribute to Sichuan’s millennia-old history. Moreover, the video also blends together cultural elements such as Sichuan hotpot, Sichuan opera, and exquisite Shu brocade and embroidery, thereby weaving tradition and modernity into a single captivating image.

Through this appearance, Sichuan, China has cordially invited global travelers to explore and experience a journey of leisurely ease and remarkable wonders.

ASTRI Showcases Six Innovative Technologies at InnoCarnival

HONG KONG, Oct. 18, 2025 /PRNewswire/ — The Hong Kong Applied Science and Technology Research Institute (ASTRI) is featuring six groundbreaking technologies and smart solutions at this year’s InnoCarnival. Spanning artificial intelligence (AI), smart mobility, medtech, contech and intelligent manufacturing, these innovations allow visitors to experience the transformative power of technology first-hand.

Organised by the Innovation and Technology Commission, the InnoCarnival officially opened today at Hong Kong Science Park and will run until 26 October. Under the theme “I&T Unlocks Your Dream“, the event aims to foster innovation and technology (I&T) culture among the public.

Ir Dr Ted Suen, Chief Executive Officer of ASTRI, reaffirmed the institute’s commitment to supporting the HKSAR Government in promoting science popularisation. He emphasised that such initiatives lay the groundwork for the robust growth of local I&T. “ASTRI remains focused on developing practical, impactful technologies that bring real benefits to society and drive efficiency across industries,” Ir Dr Suen stated. “We are proud to showcase our research achievements to the public at this annual event.”

He described InnoCarnival as a flagship occasion that draws hundreds of thousands of visitors each year, expressing hope that it will inspire more young people to pursue careers in innovation and technology, helping them unlock their potential and achieve their ambitions.

At ASTRI’s booth, visitors can engage in interactive digital technology demonstrations, enjoy generative AI games, and explore the institute’s cutting-edge innovations, including a dedicated system-on-chip for capsule endoscopy, an automated large-volume diamond colour grading instrument, drone and low-altitude economy-related technologies, and the smart optical precision positioning system tailored for modular integrated construction (MiC).

1. Wireless System-on-Chip (SoC) for Capsule Endoscopy

ASTRI’s award-winning capsule endoscopy system-on-chip, which boasts ultra-high-speed transmission capabilities more than seven times faster than traditional version, delivering significantly clearer image quality and markedly improved diagnostic accuracy. The chip is also 42% smaller than traditional designs, establishing its unique advantages in the field of capsule endoscopy and enabling patients to undergo more comfortable examinations without anaesthesia whilst reducing the risk of infection.

2. Automated Diamond Colour Grading

This high-precision automated diamond colour grading machine utilises internal reference standards to eliminate environmental and human errors, achieving an accuracy of ±0.5 grade. This innovative technology enables continuous diamond colour evaluation on production lines, simplify workflows and address the inefficiencies of traditional grading methods, setting a new benchmark for the industry.

3. Drone Technology for Urban Parcel Delivery

ASTRI’s drone solution optimises lightweight parcel delivery in urban areas, leveraging advanced positioning systems, including GNSS-RTK, inertial navigation algorithms, and roadside units (RSUs). Its precise navigation ensures reliable operation even in signal-obstructed environments, making it ideal for emergency medical deliveries. By bypassing urban traffic, the system significantly enhances delivery speed and reliability compared to conventional methods.

4. Smart Positioning for MiC Construction

ASTRI’s Smart Optic Precision Positioning System solves key challenges in Modular Integrated Construction (MiC). Using non-visible light communication (nVLC), edge computing, and event sensing, it tracks six-degree-of-freedom pose changes in real time. Features such as path prediction, operational assistance, and comprehensive hoisting records improve construction quality, enhance decision-making, and advance MiC component positioning technology.

5. Fraud Detection and Awareness Game

Fraudsters are using advanced generative AI tools, such as realistic voice cloning and deepfake technologies, making it increasingly challenging for victims to distinguish between real and fake. ASTRI’s AI fraud detection system utilises multimedia analysis, computer vision, and natural language processing to provide real-time risk alerts and fraud prevention solutions for industries like finance and insurance. At the booth, an interactive AI mini-game allows visitors to test their ability to identify authentic versus AI-generated images, helping to raise public awareness of fraud risks in the digital age.

6. ASTRI All-In-One Tech Showcase

ASTRI’s interactive digital display highlights innovations in AI, smart mobility, smart cities, advanced electronics, industrialisation, construction technology, and 5G communication. Unlike static displays, the installation allows visitors to explore ASTRI’s cutting-edge developments across diverse R&D areas through immersive visual experience.

Event website: https://innocarnival.hk/en 

ASTRI’s booth number: B07, Red Zone (G/F, 10W, Science Park)

About ASTRI

Hong Kong Applied Science and Technology Research Institute (ASTRI) was founded by the Government of the Hong Kong Special Administrative Region in 2000 with the mission of enhancing Hong Kong’s competitiveness through applied research. ASTRI’s core R&D competence in various areas is grouped under five Technology Divisions: Advanced Electronic Components and Systems; Artificial Intelligence and Trust Technologies; Communications Technologies; Intelligent Perception and Control Technologies, and IoT Sensing and AI Technologies. It is applied across six core areas which are Smart City, Financial Technologies, New Industrialisation and Intelligent Manufacturing, Digital Health, Application Specific Integrated Circuits and Metaverse.

Over the years, ASTRI has nurtured a pool of research, I&T talents and received numerous international awards for its pioneering innovations as well as outstanding business and community contributions. ASTRI has transferred close to 1,600 technologies to the industry and has been granted about 1,200 patents in the Chinese Mainland, the United States, and other countries. For further information, please visit https://www.astri.org.

Photo Download: http://bit.ly/42hqfYU 

ASTRI takes part in the InnoCarnival organised by the Innovation and Technology Commission, at Hong Kong Science Park from 18 to 26 October. Featured in the photo are Mr Michael Wong, Acting Financial Secretary of the HKSAR Government (seventh from right), Professor Sun Dong, Secretary for Innovation, Technology and Industry (sixth from right), Ms Lillian Cheong, Under Secretary for Innovation, Technology and Industry (seventh from left) and Mr Ivan Lee, Commissioner for Innovation and Technology (eighth from left), as well as legislators the Hon Eunice Yung (third from left), the Hon Duncan Chiu (second from left) and the Hon William Wong (far left)  alongside Ir Sunny Lee, Chairman of ASTRI (eighth from right), Ir Dr Ted Suen, Chief Executive Officer of ASTRI (fifth from right), and members of the R&D team
ASTRI takes part in the InnoCarnival organised by the Innovation and Technology Commission, at Hong Kong Science Park from 18 to 26 October. Featured in the photo are Mr Michael Wong, Acting Financial Secretary of the HKSAR Government (seventh from right), Professor Sun Dong, Secretary for Innovation, Technology and Industry (sixth from right), Ms Lillian Cheong, Under Secretary for Innovation, Technology and Industry (seventh from left) and Mr Ivan Lee, Commissioner for Innovation and Technology (eighth from left), as well as legislators the Hon Eunice Yung (third from left), the Hon Duncan Chiu (second from left) and the Hon William Wong (far left) alongside Ir Sunny Lee, Chairman of ASTRI (eighth from right), Ir Dr Ted Suen, Chief Executive Officer of ASTRI (fifth from right), and members of the R&D team

 

ASTRI proudly showcases its diverse research achievements at the InnoCarnival. Highlighted in the photo are Ir Sunny Lee, Chairman of ASTRI (centre), Board members, Ir Dr Ted Suen, Chief Executive Officer of ASTRI (fifth from right), and members of the R&D team
ASTRI proudly showcases its diverse research achievements at the InnoCarnival. Highlighted in the photo are Ir Sunny Lee, Chairman of ASTRI (centre), Board members, Ir Dr Ted Suen, Chief Executive Officer of ASTRI (fifth from right), and members of the R&D team

 

The ASTRI booth attracts numerous visitors to explore various interactive games and witness the real-world applications of cutting-edge technologies in everyday life
The ASTRI booth attracts numerous visitors to explore various interactive games and witness the real-world applications of cutting-edge technologies in everyday life

 

2025 “Study in Beijing” Education Exhibition Coming Soon to Vietnam and Indonesia! Face-to-face with Beijing’s Top Universities – Unlock Your Study-Abroad Opportunities

BEIJING, Oct. 18, 2025 /PRNewswire/ — A news report from CRI Online

Eager to secure a one-on-one consultation with admissions officers from Beijing’s top universities? Wish to access the latest “Study in Beijing” policies and detailed program information in one go? The 2025 “Study in Beijing” Education Exhibition is set to make a grand debut in Vietnam and Indonesia. This event serves as an exclusive bridge connecting young scholars in both nations to China’s exceptional educational resources, empowering them to realize their dreams of international academic advancement.

Two Exhibitions, Tailored to Your Study-Abroad Needs

Vietnam Stop:
09:30-16:00, October 24, Đại Nam University.
Detailed address: Second Teaching Building, Đại Nam University, No. 1, Xom Street, Phu Luong Ward, Hanoi City, Vietnam

A comprehensive breakdown of the entire application process and specific admission policies for Vietnamese students.

Indonesia Stop:
09:30-16:00, October 26, Banquet Hall, Shangri-La Hotel Jakarta

Detailed explanations of the “Study in Beijing” application procedures, scholarship opportunities, and career support services.

Elite Institutions Gathered, Tailored to Southeast Asian Development Needs

This exhibition brings together over 10 leading universities from Beijing, covering a wide range of high-demand disciplines — from business and science & technology, to languages and agriculture. These institutions are carefully selected to align with the academic interests and career aspirations of students in Vietnam and Indonesia:

Tsinghua University, Peking University, Beijing Normal University, China Agricultural University, Communication University of China, North China Electric Power University, Beijing Foreign Studies University, Minzu University of China, Beijing Jiaotong University, University of Science and Technology Beijing, Capital Medical University, Beijing University of Chinese Medicine, Beijing University of Civil Engineering and Architecture, North China University of Technology, Beijing Technology and Business University, Beijing Polytechnic University, Beijing College of Finance and Commerce.

Three Core Advantages to Smooth Your Path to Studying Abroad!

Precision Alignment of Policies and Aspirations:

Admissions officers will provide on-site interpretations of the 2025 “Study in Beijing” Special Scholarships. They will also shed light on admission preferences for highly sought-after disciplines like information technology and business, helping you overcome information asymmetries.

Personalized Consultation:

Based on your academic background and career goal, admissions teams can offer customized advice to help you find the most suitable institution and program.

Immersive Experience of Chinese Education:

Gain first-hand insights into the bilingual teaching systems and cross-cultural support services offered by Beijing’s universities. Get a head start by experiencing campus environments virtually and planning your student life in advance.

From Hanoi to Jakarta, the 2025 “Study in Beijing” Education Exhibition is committed to supporting you every step of the way! Mark your calendars: October 24 at Đại Nam University, Vietnam, and October 26 at Shangri-La Hotel Jakarta. Engage face-to-face with Beijing’s top-tier universities and embark on your journey of international growth!

Manulife Hong Kong and JUST FEEL Promote Emotional Well-Being with City’s First “My Flag Day”

500 family volunteers distribute over 10,000 free flags to encourage the public to share their feelings

HONG KONG, Oct. 18, 2025 /PRNewswire/ — Manulife Hong Kong and JUST FEEL, a Hong Kong-based NGO dedicated to emotional education, successfully held the city’s first-ever “My Flag Day” today. A total of 500 family volunteers from Manulife and nine of JUST FEEL’s partner schools engaged with 10,000 citizens across the city, encouraging them to select a flag to wear, which would represent their current feelings. This initiative aims to raise public awareness of self-care by acknowledging and sharing different emotions.

“My Flag Day” introduced a creative concept that encouraged individuals to focus on their own well-being and express their feelings through personalized flags. The Feeling Flags, which were distributed for free, were winning designs from the “My Flag Day” Flag Paper Design Competition held earlier this year. Illustrated by local primary school students, the flags represent six positive and negative feelings, including “happy”, “warm”, “excited”, “sad”, “angry”, and “scared”. By putting on these flags, people brought otherwise unspoken feelings into life, reinforcing the message that feelings are neither right nor wrong. These flags also served as conversation starters, inspiring people to share and, in turn, deepen mutual understanding and care.

Since April 2025, Manulife and JUST FEEL have forged a multi-year strategic charity partnership to nurture students’ emotional well-being and cultivate a “Compassionate School Culture”. The collaboration also aligns with Manulife’s Impact Agenda, underscoring the company’s strong commitment to empowering sustained health and well-being within the community. As one of the flagship initiatives, “My Flag Day” brings this shared vision of emotional wellness beyond schools and into the public. It advocates for active listening, acceptance, and expression of feelings as a way to prevent emotional suppression. By mobilizing 500 family volunteers, Manulife and JUST FEEL also inspired families to explore feelings together, strengthen parent‑child relationships, and engage with their neighborhoods in more caring ways. 

“Mental well-being is a vital pillar of overall health and is essential to living a fulfilling life. At Manulife, we are committed to fostering mental wellness as part of our broader mission to empower sustained health and well-being. We believe that creating space for people to openly express and embrace all feelings is key to building a healthier, more resilient society. We are pleased to partner with JUST FEEL to launch Hong Kong’s first ‘My Flag Day’ – a meaningful initiative that advances public awareness on emotional well-being and promotes empathy and compassion across our communities,” said Celia Ling, Chief Marketing Officer of Manulife Hong Kong and Macau.

“Expressing our feelings with courage and sincerity is crucial for fostering well-being and building healthy relationships. We are grateful to Manulife and our partner schools for their continuous support and for joining us on this journey. Through ‘My Flag Day’, we have extended emotional education from schools to families and the wider community. Looking ahead, we will continue to work closely with Manulife to promote compassionate communication and social‑emotional learning across local schools, transforming the communication culture in schools and families, thereby enhancing students’ emotional well-being,” said Raymond Yang, Co-founder and Executive Director of JUST FEEL.

Manulife and JUST FEEL, a Hong Kong-based NGO dedicated to emotional education, successfully held Hong Kong's first-ever
Manulife and JUST FEEL, a Hong Kong-based NGO dedicated to emotional education, successfully held Hong Kong’s first-ever “My Flag Day” today. Five hundred family volunteers engaged with 10,000 citizens across the city, encouraging them to select a flag to wear, which would represent their current feelings. This initiative calls for public awareness of self-care by acknowledging and sharing different feelings.

 

Raymond Yang, Co-founder and Executive Director of JUST FEEL, and Celia Ling, Chief Marketing Officer, Manulife Hong Kong and Macau, joined My Flag Day to cheer for the volunteers.
Raymond Yang, Co-founder and Executive Director of JUST FEEL, and Celia Ling, Chief Marketing Officer, Manulife Hong Kong and Macau, joined My Flag Day to cheer for the volunteers.

 


 


 

The family volunteers from Manulife and nine JUST FEEL partner schools invited the public to share their feelings and actively distributed the Feeling Flags.
The family volunteers from Manulife and nine JUST FEEL partner schools invited the public to share their feelings and actively distributed the Feeling Flags.

About Manulife Hong Kong
Manulife Hong Kong has been a trusted name for more than 125 years. Since our operations started in Asia in 1897, we have grown to become one of the top-tier providers of financial services, offering a diverse range of protection and wealth products and services to over 2.6 million customers in Hong Kong and Macau. We are committed to helping make decisions easier and lives better for our customers.

Manulife Hong Kong, through Manulife International Holdings Limited, owns Manulife (International) Limited, Manulife Investment Management (Hong Kong) Limited, and Manulife Provident Funds Trust Company Limited. These entities are all subsidiaries of Manulife Financial Corporation.

About Manulife
Manulife Financial Corporation is a leading international financial services provider, helping our customers make their decisions easier and lives better. With our global headquarters in Toronto, Canada, we operate as Manulife across Canada, Asia, and Europe, and primarily as John Hancock in the United States, providing financial advice and insurance for individuals, groups and businesses. Through Manulife Wealth & Asset Management, we offer global investment, financial advice, and retirement plan services to individuals, institutions, and retirement plan members worldwide. At the end of 2024, we had more than 37,000 employees, over 109,000 agents, and thousands of distribution partners, serving over 36 million customers. We trade as ‘MFC’ on the Toronto, New York, and the Philippine stock exchanges, and under ‘945’ in Hong Kong.

Not all offerings are available in all jurisdictions. For additional information, please visit manulife.com

About JUST FEEL
JUST FEEL is the first charity to systematically promote Compassionate Communication and Social-Emotional Learning in local schools in Hong Kong. With the motto of “Connection before Solution”, JUST FEEL is dedicated to transforming the communication culture in schools and families, empowering educators and parents to enhance the emotional well-being of children. Since its establishment in 2018, JUST FEEL has collaborated with over 65 primary schools, supporting over 55,300 students, 8,900 teachers, and 87,300 parents. For additional information, please visit https://www.justfeel.hk/.

Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session

SUZHOU, China, Oct. 18, 2025 /PRNewswire/ — Alphamab Oncology (Stock Code: 9966.HK) announced that the first interim analysis results of a phase III clinical trial of anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with chemotherapy as second-line or above treatment of HER2-positive gastric cancer (GC) (including gastroesophageal junction cancer (GEJ)) (Study ID: KN026-001, also known as KC-WISE), have been presented at the 2025 European Society for Medical Oncology Congress (ESMO Congress 2025) Late-Breaking Abstract (LBA) Oral Presentation Session.

LBA Oral Presentation Session is a highly anticipated global highlight of the ESMO Congress. The research presented in this category is both highly topical and of significant clinical value. Their findings often herald potential impacts on current clinical practice and can even guide the future direction of entire therapeutic fields.

TitleKN026 in combination with chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Interim analysis of KC-WISE
Number: LBA 78
Speaker: Jianming Xu, Chinese PLA General Hospital
DateFriday, 17 October 2025

METHODS

Enrolled patients in study KN026-001 (KC-WISE) with HER2-positive GC/GEJ who had disease progression after trastuzumab-based therapy were randomized to receive either anbenitamab (KN026) in combination with chemotherapy (the “Anbenitamab Group”) or chemotherapy with placebo (the “Control Group”). The patients were stratified based on (i) type of chemotherapy, (ii) HER2 expression level, and (iii) number of prior lines of treatments.

RESULTS

At baseline, patient characteristics were generally well balanced between the two groups. The median age was approximately 64 in the Anbenitamab Group and 61 in the Control Group. In both groups, over 80% of patients had an ECOG PS of 1, and nearly all patients were diagnosed with stage IVB disease at enrollment. All patients had previously received chemotherapy, most commonly taxanes (over 70%), with the remainder receiving irinotecan-based regimens.

As of April 3, 2025, the median follow-up duration was 9.7 months (95% CI, 7.2 to 11.9 months) in the Anbenitamab Group and 9.8 months (95% CI, 7.4 to 12.9 months) in the Control Group.

Efficacy as assessed by the Independent Review Committee (IRC):

  • The median treatment-related adverse event (PFS) for the Anbenitamab Group was 7.1 months, compared with 2.7 months in the Control Group. The hazard ratio (HR) is 0.25 (P value is 5.44 × 10⁻¹²), corresponding to a 75% reduction in the risk of disease progression or death.
  • The median overall survival (OS) for the Anbenitamab Group was 19.6 months (not mature), compared with 11.5 months in the Control Group. The HR is 0.29, representing a 71% reduction in the risk of death, and P value is 1.56 × 10⁻6, which is well below the prespecified extremely stringent alpha threshold of 0.00001.
  • The objective response rate (ORR) was 55.8% in the Anbenitamab Group versus 10.8% in the Control Group, while the disease control rate (DCR) was 80.0% and 41.9%, respectively. The median duration of response (DoR) was 8.2 months and 2.9 months, respectively.

Safety:

  • The median treatment duration was 6.5 cycles in the Anbenitamab Group and 3.0 cycles in the Control Group.
  • The incidence of Grade 3 treatment-emergent adverse events (TEAEs) or above was 60.6% in the Anbenitamab Group and 51.6% in the Control Group, while the incidence of serious adverse events (SAEs) was 31.9% and 33.3%, respectively.
  • The most frequently observed Grade 3 treatment-related adverse events (TRAEs) or above in the Anbenitamab Group included neutropenia (29.8%), leukopenia (21.3%), anemia (18.1%), diarrhea (8.5%) and asthenia (8.5%), while the most frequently observed Grade 3 TRAEs or above in the Control Group included leukopenia (24.7%), neutropenia (21.5%), anemia (10.8%), diarrhea (7.5%) and thrombocytopenia (5.4%). The incidence of cardiotoxicity in both groups were both 3.2%, indicating fewer cardiac concerns.

CONCLUSIONS

The interim analysis demonstrated that anbenitamab achieved superior efficacy in second-line or third-line HER2-positive gastric cancer patients who had been previously treated with trastuzumab. The study met both its primary endpoints of PFS and OS with statistically significant and clinically meaningful improvements, indicating its potential to change clinical practice guidelines for the treatment of second-line or above gastric cancer. Compared with the recently published DESTINY-Gastric04 results of DS-8201 in second-line gastric cancer, anbenitamab demonstrates potential advantages in both efficacy and safety.

Prompted by these encouraging results of anbenitamab, we are preparing to expand clinical development into first-line and perioperative gastric cancer through new registrational trials, aiming to extend benefits to more patients. Meanwhile, JSKN003, an ADC built upon KN026, has demonstrated high-security profile and distinctive advantages. With multiple registrational studies currently advancing as planned, we anticipate even more outstanding performance from JSKN003 in the future.

About Anbenitamab (KN026)

Anbenitamab (KN026) is an anti-HER2 bispecific antibody independently developed by Alphamab Oncology using the proprietary Fc-based heterodimer bispecific platform technology called CRIB (Charge Repulsion Induced Bispecific). KN026 can simultaneously bind two non-overlapping epitopes of HER2, resulting in HER2 signal blockade.

Results from multiple clinical studies showed that KN026 has promising efficacy for the treatment of HER2-positive solid tumors, both in the first-line and in patients previously treated with trastuzumab. Currently, several pivotal trials of KN026 for second-line or above HER2-positive GC/gastroesophageal junction cancer (GEJ), first-line HER2-positive BC, neoadjuvant treatment of HER2-positive BC are being conducted. KN026 for the treatment of patients with HER2-positive GC  who have failed first-line standard treatment was granted breakthrough therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China (NMPA). KN026 for the treatment of HER2-positive or low expressing GC was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). In September 2025, the first New Drug Application (NDA) for anbenitamab injection has been accepted by the NMPA for use in combination with chemotherapy in patients with HER2-positive locally advanced, recurrent, or metastatic GC/GEJ who have failed at least one prior systemic therapy (which must include trastuzumab in combination with chemotherapy).

In August 2021, the Company entered an agreement with JMT-Bio Technology Co., Ltd. (“JMT-Bio”), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (stock code: 1093.HK), for the development and commercialization of KN026 in Mainland China. JMT-Bio was granted exclusive license rights of KN026 for the development and commercialization in the indications of BC an GC/GEJ in Mainland China (excluding Hong Kong, Macau and Taiwan).

About Alphamab Oncology

Alphamab Oncology is an innovative biopharmaceutical company focused on oncology. On December 12, 2019, the Company was successfully listed on the Main Board of the Hong Kong Stock Exchange (Stock Code: 9966.HK).

Leveraging proprietary platforms-including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations-the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.

One product has received market approval: Envafolimab (KN035, brand name: 恩维达®), the world’s first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Four bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines—such as dual-payload ADCs—are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide.

From “Wheels” to a “Three-Dimensional Ecosystem”: The 2025 Chery Global Innovation Conference Unveils a New Blueprint for Intelligent Mobility

WUHU, China, Oct. 18, 2025 /PRNewswire/ — A clear and composed “Hello everyone, I’m Mornine” ignited the climax of the 2025 Chery Global Innovation Conference.

This unique “presenter” was none other than AiMOGA robot Mornine.

In a ten-minute fully autonomous presentation, she reviewed AiMOGA’s journey from concept to real-world deployment across more than 30 countries and demonstrated multilingual interaction and scenario-based applications, outlining a vivid vision of “car-machine collaboration.”

AiMOGA Robot “Mornine” on stage at the Innovation Conference
AiMOGA Robot “Mornine” on stage at the Innovation Conference

Mornine’s remarkable appearance became a vivid illustration of the conference theme, “Innovation • Intelligence Leading the World.”

As one of the core activities of the 2025 Chery International User Summit, the Innovation Conference brought together academicians, top global experts, industry leaders, media, and partners to witness Chery’s breakthrough transformation toward a full-scenario intelligent ecosystem.

From Presenter to Experience Officer: A Robots Ecosystem Showcase

Mornine’s highlights extended beyond the main stage.

In the outdoor demonstration area, her “multi-agent collaboration” became another focus of attention.

From professional introductions and vehicle guidance to door-opening demonstrations, every step was completed autonomously.

With the coordination of her vision-tactile dexterous hand and multi-expression interaction system, Mornine impressed visitors with fluent demonstrations—pouring water, opening car doors, and other signature actions that drew rounds of applause.

Dr. Gao Xinhua delivers a keynote presentation
Dr. Gao Xinhua delivers a keynote presentation

Dr. Gao Xinhua, CTO of Chery Group, stated during his keynote:

“Our technology evolution is expanding from ‘wheels’ to a ‘three-dimensional ecosystem,’ and intelligent robots are a natural extension of this strategy.”

This vision is reflected in AiMOGA’s technical details:

its ±5 cm precision autonomous navigation and dynamic obstacle avoidance builds on Chery’s achievements in intelligent driving;

and its 17-degree-of-freedom vision-tactile dexterous hand integrates Chery’s electromechanical and control system expertise.

The Strength of “Tech Chery”: Five Domains of Breakthrough Innovation Behind AiMOGA’s impressive performance lies the technological foundation of “Tech Chery.”

At this year’s Innovation Conference, Chery unveiled major breakthroughs across five key technology domains, releasing more than ten world-leading innovations.

The new Kunpeng engine set a new global benchmark with over 48% thermal efficiency;

the high-energy solid-state battery achieved 600 Wh/kg, near the theoretical lithium limit;

the Luoshu AI large model covers 1,000+ vehicle control functions, with response time <1000 ms and task accuracy >95%;

the Falcon 900 intelligent driving system integrates VLA and world modeling, targeting L3–L4 autonomous driving with full safety redundancy.

From leading hybrid performance to human-centered intelligent interaction, from key breakthroughs to full-ecosystem development, Chery is transforming its 28 years of technological expertise into a key to the future — opening a new era of global intelligent mobility.

From Wuhu to the World: A New Global Identity for the Future

Just before the conference, AiMOGA Robotics achieved a series of EU certifications, becoming the world’s first robot to complete both hardware and software compliance. This milestone marks a new chapter in Chery’s global ecosystem — from Poland to Malaysia, Indonesia to South Africa, AiMOGA Dedicated To Embodied Intelligence. Be Committed To Building World-Leading And Trusted AI Assistants. Behind this growing global footprint lies AiMOGA’s powerful R&D network — spanning Shanghai, Europe, and North America, and collaborating with top universities.

This multidimensional R&D ecosystem fuels AiMOGA’s ongoing evolution and serves as a strong foundation for Chery’s global innovation strategy.

AiMOGA Robot interactive experience zone outside the venue
AiMOGA Robot interactive experience zone outside the venue

From AiMOGA Robotics leading the era of embodied intelligence to Chery’s progress across five technological frontiers, a new vision of intelligent mobility is emerging.

Within this ecosystem, robots have become the natural bridge between people, vehicles, and services.

From showrooms to city blocks, from production lines to living spaces, Chery is building a future where humans and robots coexist harmoniously and technology integrates seamlessly with real-world scenarios.

At this moment, on the stage of the 2025 Chery Global Innovation Conference, we are witnessing not just a product release, but the beginning of a new era.

Looking ahead, Chery will continue to drive innovation and speak the language of intelligence, joining global partners to usher in a new era of human-robot symbiosis and intelligent connectivity.

SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025

SINGAPORE, Oct. 18, 2025 /PRNewswire/ — SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing next-generation immunotherapies for infectious diseases and their associated cancers, announced the presentation of first-in-human clinical data for SCG142 in an investigator-initiated Phase I trial (NCT06544720) in patients with recurrent or metastatic HPV-associated carcinomas. The poster will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, on Saturday, 18 October 2025.

This ongoing first-in-human trial evaluates the safety, tolerability and preliminary efficacy of SCG142, a novel human papillomavirus (HPV) E7-specific T-cell receptor-engineered T (TCR T) cell therapy armoured with a TGFβRII-41BB chimeric switch receptor. Eligible patients are HLA-A*02:01-positive with advanced HPV16- or HPV52-positive carcinomas who have progressed on or were intolerant to at least one prior systemic therapy. Key endpoints include safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity. As of the data cut-off, tumor shrinkage was observed in all seven treated patients, resulting in a disease control rate (DCR) of 100%. Four of the seven patients (57%) achieved >30% tumor reduction, including two confirmed partial responses (PR) and two unconfirmed PRs. No dose-limiting toxicities or serious adverse events were reported. These preliminary findings support continued clinical development of SCG142.

“SCG142 is a novel and differentiated HPV-specific TCR T cell therapy with promising clinical activity.” said Prof. Dr. Yang Li, Director of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University. “We’re excited that tumor shrinkage was observed in all seven treated patients and that SCG142 was well tolerated. These encouraging preliminary findings underscore the potential of SCG142 to provide new solutions for patients in a variety of HPV16 and HPV52 expressing cancers and support further evaluation in larger patient cohorts”, she added.

SCG142 was isolated with GianTCRTM, SCG’s proprietary TCR screening platform with the ability to identify fully natural TCRs with high affinity and high avidity properties as well as potent antiviral and anti-tumor effects against infection-related solid tumors accompanied by a lower risk of off-target toxicity. “We are delighted that the excellent preclinical profile of our HPV-E7-specific TCR – including high avidity and dual functionality in both CD8+ and CD4+ T cells – has translated into clinical activity with SCG142″ added Dr. Susanne Wilde, VP, Head of Preclinical Research of SCG Cell Therapy.

Besides SCG142, SCG is also advancing SCG101, a hepatitis B virus (HBV)-specific TCR T cell therapy for the treatment of HBV-related hepatocellular carcinoma (HCC).

– END –

About Human Papillomavirus and Cancers

Human papillomavirus (HPV) infection is the most common sexually transmitted infection. Nearly all sexually active people are infected with HPV and around half of these infections occur with a high-risk HPV type, which can lead to cancer development.1 As such, HPV infection accounts for more than 90% of anal and cervical cancers, about 70% of vaginal and vulvar cancers, and 60% of penile and oropharyngeal cancers, and it causes an estimated 690,000 cancers worldwide each year[1],[2].

About SCG Cell Therapy

SCG is a leading biotechnology company focusing on the development of novel immunotherapies in infections and its associated cancers. The company targets the most common cancer-causing infections:  HPV, HBV and EBV, and develops a broad and unique pipeline of TCR-based cellular immunotherapy products against infection- associated cancers. With the proprietary GianTCRTM TCR screening platform, in house viral vector production and AutoCellTM, a fully closed, automatic and low-cost cell therapy manufacturing system, the company covers the entire value chain from new target research and discovery, manufacturing, and clinical development. For more information about SCG, please visit us at www.scgcell.com.

[1] HPV and cancer. National Cancer Institute. (2025, May 9)

[2] Basic information about HPV and cancer. Centers for Disease Control and Prevent (2024, September 17)

 

 

Joyful Alliance Proposes Sustainable Integrated Onsen Resort to Japan’s Wakayama City, Targeting the World’s First Zero-Carbon Destination with USD 2.2 B Investment


HONG KONG SAR – Media OutReach Newswire – 18 October 2025 – Joyful Alliance, a Singapore-headquartered investment firm, today announced it will propose the development of the Wakayama Integrated Onsen Resort to the Wakayama City Government. The two parties officially signed the memorandum of cooperation on October 17.

Joyful Alliance will propose an Integrated Onsen Resort development in Wakayama City, Japan, projected to attract millions of visitors annually. (From right to left) Mr. Simon Chua, Executive Counsel for the Wakayama City Urban Regeneration Corporation; Mr. Thomas Tin, Managing Director of Joyful Alliance; Ms. Sherleen Tay, General Manager of Green Matter Hub; and Mr. Ryan Lau, Representative of CMA Testing.
Joyful Alliance will propose an Integrated Onsen Resort development in Wakayama City, Japan, projected to attract millions of visitors annually. (From right to left) Mr. Simon Chua, Executive Counsel for the Wakayama City Urban Regeneration Corporation; Mr. Thomas Tin, Managing Director of Joyful Alliance; Ms. Sherleen Tay, General Manager of Green Matter Hub; and Mr. Ryan Lau, Representative of CMA Testing.

Joyful Alliance is actively discussing a future investment in Wakayama City of over US$2.2 billion, aiming to leverage Wakayama City’s rich natural hot springs and cultural heritage to create the World’s first zero-carbon resort. Upon completion, the resort is expected to draw millions of visitors annually, injecting new vitality into Wakayama City’s tourism sector.

Wakayama City lies in Japan’s Kansai region, adjacent to Osaka. It is well connected: the site is a 30-minute drive from Kansai International Airport. The proposed Wakayama Integrated Onsen Resort is planned to be a green, zero-carbon smart resort that combines Wakayama’s millennia-old Onsen culture with entertainment facilities.

Joyful Alliance, backed by family offices from Hong Kong and Singapore, specialises in green investments, asset management and sustainable infrastructure projects. For the Wakayama Integrated Onsen Resort development proposal, Joyful Alliance has assembled an international team of partners: Green Matter Hub, a green technology platform, will supply low-carbon construction materials and intelligent energy solutions; and CMA Testing will oversee quality assurance, ensuring that every aspect of the project meets global sustainability standards.

Mr. Simon Chua, Executive Counsel for the Wakayama City Urban Regeneration Corporation, stated: “Wakayama City is a historic gem blessed with natural beauty, rich culture, and a strategic location. I am very pleased to invite Joyful Alliance to discuss this potential transformative investment.”

Mr. Thomas Tin, Managing Director of Joyful Alliance, emphasised: “We are honoured to be invited to discuss this historic project. We believe this project will generate tens of thousands of jobs in surrounding areas and lead the industry with green zero-carbon technologies. Given our background in green technology, we hope to bring outstanding green tech innovations from Hong Kong to collaborate locally when building in Japan. We will leverage our expertise in green investment and sustainable development to work with the team to propose a resort imbued with Wakayama City’s local character.”

Ms. Sherleen Tay, General Manager of Green Matter Hub, noted: “We are thrilled to support the upcoming Wakayama project in achieving carbon neutrality. Through our digital ecosystem, including combining certification, carbon tracking, and fintech services, we’re shaping a low-carbon future.”

Mr. Ryan Lau, representative of CMA Testing, added: “As a greenhouse verification body, we will provide expert guidance to ensure that every step of this project aligns with international standards while honouring Japan’s local regulations and environmental goals.”

Hashtag: #JoyfulAlliance

The issuer is solely responsible for the content of this announcement.

Joyful Alliance

Joyful Alliance is a forward-looking investment company based in Singapore, backed by a consortium of family offices from both Hong Kong and Singapore. We are committed to delivering long-term value to our clients through strategic asset management, innovative financial solutions, and disciplined investment practices.

Our services are grounded in the principles of integrity and performance, catering to a diverse clientele ranging from individual investors to institutional partners. For more information, visit .